← Insider Monitor
Stoke Therapeutics, Inc. logo
STOK

Stoke Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations

6
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Stoke Therapeutics is a biopharmaceutical company developing antisense oligonucleotide medicines that restore protein levels by targeting RNA, with lead programs focused on genetic epilepsies such as Dravet syndrome and other diseases caused by haploinsufficiency.

Industry
Pharmaceutical Preparations
Headquarters
Bedford, MA
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Kaye Edward M. MDInsiderSell$382KAug 18, 2026
Ticho BarryCHIEF MEDICAL OFFICERSell$145KAug 18, 2026
Allan JonathanGENERAL COUNSEL & CORP SECSell$87KAug 18, 2026
Kaye Edward M. MDInsiderSell$21KAug 18, 2026
Ticho BarryCHIEF MEDICAL OFFICERSell$8KAug 18, 2026
Allan JonathanGENERAL COUNSEL & CORP SECSell$5KAug 18, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for STOK.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable STOK activity by email

Free alerts for the insider and congressional trades worth watching.

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.